Evidence map›Paper›PMID 29891985›Full record

ArticleScientific reports2018

Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays.

Debabrata Mahapatra, Jill A Franzosa, Kyle Roell, Melaine Agnes Kuenemann, Keith A Houck, David M Reif, Denis Fourches, Seth W Kullman

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Debabrata MahapatraComparative Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Jill A FranzosaNational Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, RTP, Raleigh, North Carolina, USA.
Kyle RoellDepartment of Chemistry, Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, USA.
Melaine Agnes KuenemannDepartment of Chemistry, Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, USA.
Keith A HouckNational Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, RTP, Raleigh, North Carolina, USA.ORCID 0000-0002-0055-2249
David M ReifDepartment of Chemistry, Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, USA.ORCID 0000-0001-7815-6767
Denis FourchesDepartment of Chemistry, Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, USA.
Seth W KullmanDepartment of Biological Sciences, North Carolina State University, Raleigh, North Carolina, USA. swkullma@ncsu.edu.
North Carolina State University · USEnvironmental Protection Agency · US

Funding

Translational Research Support CoreP30ES025128 · NIEHS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Andrew R. Binder · 2015 to 2026
$18.3M
GRADUATE TRAINING IN BIOINFORMATICST32ES007329 · NIEHS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Fred A. Wright · 2000 to 2026
$6.8M
NIEHS NIH HHS P30 ES025128NIEHS NIH HHS T32 ES007329
6 · The paper itself

Abstract

High throughput screening (HTS) programs have demonstrated that the Vitamin D receptor (VDR) is activated and/or antagonized by a wide range of structurally diverse chemicals. In this study, we examined the Tox21 qHTS data set generated against VDR for reproducibility and concordance and elucidated functional insights into VDR-xenobiotic interactions. Twenty-one potential VDR agonists and 19 VDR antagonists were identified from a subset of >400 compounds with putative VDR activity and examined for VDR functionality utilizing select orthogonal assays. Transient transactivation assay (TT) using a human VDR plasmid and Cyp24 luciferase reporter construct revealed 20/21 active VDR agonists and 18/19 active VDR antagonists. Mammalian-2-hybrid assay (M2H) was then used to evaluate VDR interactions with co-activators and co-regulators. With the exception of a select few compounds, VDR agonists exhibited significant recruitment of co-regulators and co-activators whereas antagonists exhibited considerable attenuation of recruitment by VDR. A unique set of compounds exhibiting synergistic activity in antagonist mode and no activity in agonist mode was identified. Cheminformatics modeling of VDR-ligand interactions were conducted and revealed selective ligand VDR interaction. Overall, data emphasizes the molecular complexity of ligand-mediated interactions with VDR and suggest that VDR transactivation may be a target site of action for diverse xenobiotics.

Indexed as

Drug Evaluation, PreclinicalGenes, ReporterHigh-Throughput Screening AssaysHumansLuciferasesProtein BindingReceptors, CalcitriolTwo-Hybrid System TechniquesXenobioticsLuciferasesReceptors, CalcitriolVDR protein, humanXenobiotics

Identifiers

PMID29891985
PMCPMC5995905
OpenAlexW2805396627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.